[12] Patent
[11] Patent No.:GC0007571  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126004
Date of the Decision to Grant the Patent:15/Apr/2018

[21] Application No.:GC 2011-17641

[22] Filing Date:24/1/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
26/1/2010
101517233

[72] Inventors:1- Siegfried SCHNEIDER،2- Dirk KESSLER،3- Lars Van der VEEN،4- توبياس وونبيرج

[73] Owner: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Binger Strasse 173, 55216 , Ingelheim am Rhein, Germany

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/505, 31/506; A61P 35/00; C07D 239/26, 401/06, 401/14, 405/14, 409/14, 413/14, 471/04, 487/08 (2006.01)

[56] Cited Documents:

-WO 2008155140 A1 (BAYER SCHERING PHARMA AG [DE]; HARTUNG INGO [DE]; BOTHE ULRICH [DE]; K) 24 December 2008
-WO 2006103449 A2 (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; JONES CLIFFORD DAVID [GB]) 5 October 2006
-WO 2006044823 A2 (AMGEN INC [US]; CHAFFEE STUART C [US]; ALBRECHT BRIAN K [US]; HODOUS B) 27 April 2006
 
Examiner: PH. Nada M. AlBehaiji

[54] 5-ALKYNYL-PYRIMIDINES
[57] Abstract: The present invention encompasses compounds of general formula (1), wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
No. of claims: 14


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.